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Introduction
Neuropsychiatric systemic lupus erythematosus (NP-
SLE) is a serious and potentially life-threatening mani-
festation of lupus, occurring in 25–70% of cases, and
associated with an increased risk of death [1]. Patients
present with a wide range of central (CNS) and
peripheral nervous system deficits. Patients who also
have antiphospholipid antibodies (APL-Ab) are at
additional risk for neuropsychiatric events. Patients with
lupus are also at increased risk for a wide range of CNS
events related to immunosuppressive therapy, including
infection and drug toxicity. Unrelated but common
neurologic disorders, such as migraine or multiple scle-
rosis, may be difficult to distinguish from NP-SLE.
CNS vasculitis, an important, potentially severe form
of NP-SLE, may present with seizures, movement dis-
orders, altered consciousness, stroke, or coma [2]. While
a true inflammatory vasculitis is uncommon, the clini-
cian must entertain this diagnosis when a patient with
lupus has CNS signs or symptoms. Diagnosis of CNS
vasculitis can be difficult, as the definitive test, brain
biopsy, is infrequently performed. Empiric treatment,
based on the serologic and imaging data, is therefore
common.
In addition to the history and examination, other
diagnostic approaches include serologic tests for active
lupus (C-reactive protein, complement, anti-DS DNA)
and analysis of cerebrospinal fluid [3, 4]. However,
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Abstract Our objective was to
review the frequency and pattern of
signal abnormalities seen on con-
ventional MRI in patients with
suspected neuropsychiatric systemic
lupus erythematosus (NP-SLE). We
reviewed 116 MRI examinations of
the brain performed on 85 patients
with SLE, (81 women, four men,
aged 21–78 years, mean 40.6 years)
presenting with neurological distur-
bances. MRI was normal or nearly
normal in 34%. In 60% high-signal
lesions were observed on T2-weigh-
ted images, frequently in the frontal
and parietal subcortical white mat-
ter. Infarct-like lesions involving
gray and white matter were demon-
strated in 21 of cases. Areas of
restricted diffusion were seen in 12 of
the 67 patients who underwent
diffusion-weighted imaging. Other
abnormalities included loss of brain
volume, hemorrhage, meningeal
enhancement, and bilateral high
signal in occipital white-matter. The
MRI findings alone did not allow us
to distinguish between thromboem-
bolic and inflammatory events in
many patients. Some patients with
normal MRI improved clinically
while on immunosuppressive ther-
apy. More sensitive and/or specific
imaging methods, such as spectros-
copy and perfusion-weighted imag-
ing, should be investigated in these
subgroups of patients with suspected
NP-SLE.
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lupus, and angiography may be abnormal in as few as
5–10% of patients because of the small size of the vessels
involved [5]. Diagnosis strongly relies on MRI; while the
MRI manifestations of NP-SLE have been the subject of
numerous reports [6, 7, 8, 9, 10, 11, 12, 13, 14], the
impact of the findings on management is not clear. Our
purpose was to characterize the MRI findings in patients
presenting with a wide spectrum of neurologic disease,
classified according to the new SLE case definitions, and
to correlate them with the clinical course to evaluate the
role of MRI in diagnosis and management.
Materials and methods
We reviewed 116 MRI studies of 85 patients enrolled in the Uni-
versity of Michigan SLE cohort. All research was performed in
accordance with our institutional review board and with the in-
formed consent of the participants. Patients were included if they
fulfilled the 1982 Revised Criteria for SLE set forth by the Amer-
ican Rheumatism Association [15] and had complete MRI of the
brain for neurologic symptoms or signs. During the period
1993–2001, 23 patients were imaged twice and five were examined
three or more times.
We defined complete MRI of the brain as a minimum of T1-
and T2-weighted images, and either proton density (PD)-weighted
or fluid-attenuated inversion-recovery (FLAIR) images, including
at least two orthogonal planes. All examinations were performed at
1.5 Tesla. Contrast medium was given in 93 of the 116 studies,
followed by axial/sagittal/coronal T1-weighted images. In
67 studies we obtained echoplanar diffusion-weighted imaging
(DWI: b=1000 s/mm2, TE 89 TR 10 000ms, filed of view 22 cm,
one excitation, matrix 128·128). We carried out time-of-flight
MRA of the cerebral vessels on 16 patients and MR venography of
the dural venous sinuses on four. We performed catheter angiog-
raphy on three patients, to exclude SLE-related CNS vasculitis.
All MRI studies were reviewed in consensus by two neurora-
diologists (PCS, PM) and one radiology resident (JJ). Images were
scored for loss of brain volume (none, mild, moderate, severe),
abnormal signal, abnormal contrast enhancement, abnormal dif-
fusion, hemorrhage or mineralization, and any other abnormalities.
Brain lesions were classified as infarct-like (moderate-size to large,
roughly wedge-shaped areas of abnormal high signal on
T2-weighted images and/or encephalomalacia involving gray and
white matter) or white-matter lesions (subcortical, deep, or peri-
ventricular, punctate or patchy). The site and number of the lesions
were also noted. When patients had more than one examination,
we classified lesions as stable, resolving, or progressing. DWI was
examined for areas of restricted or increased diffusion, using
apparent diffusion coefficient (ADC) where available. Subsequent
comparison with the initial reports revealed no significant dis-
crepancies. The consensus panel did not review the catheter angi-
ograms.
Clinical data extracted were age, sex, and race, disease char-
acteristics (primary and secondary diagnoses, duration of diagno-
sis, medications, and presence of APL-Ab) (Table 1), symptoms
and signs, neurologic and pathologic diagnoses, therapy, and
clinical course. Presenting symptoms or signs were classified
according to the 1999 American College of Rheumatology
Nomenclature and Case Definitions for Neuropsychiatric Lupus
Syndromes [2] (Table 2). Presentations were divided into one of the
following groups: global disease (including acute confusional state,
cognitive decline, and psychosis), focal disease (stroke, cranial
neuropathies), headache, seizures, and complex presentations
(multiple deficits or difficult to place into any of the other
categories). Statistical analyses of these subgroups were performed
using Fishers exact test.
Results
Imaging findings are summarized in Table 3. About one
third (34%) of the patients had normal MRI. Of these,
41% presented with headache as a major symptom, and
patients presenting with only headaches were signifi-
cantly more likely to have normal MRI than those with
all other presentations (P=0.03). Patients with normal
MRI were less than half as likely to present with seizures
than those with abnormal MRI (7% vs 17%), although
the difference was not significant (P=0.27). Parenchy-
mal volume loss was found in 43% of patients,
predominantly mild and diffuse.
Abnormal signal was typically high on FLAIR and
other T2-weighted images, most frequently in the frontal
and parietal subcortical white matter, although it could
appear anywhere in the brain, including the brain stem.
Most (32) of the patients with high-signal foci had five or
Table 1 Details of the 85 patients studied
Sex 81 female, 4 male




Duration of disease 0–41 yrs (mean 8.6 yrs)
MCTD/lupus overlap syndromes 4







Table 2 Presenting symptoms or signs, classified according to the
1999 American College of Rheumatology Nomenclature and Case
Definitions [2]
Central nervous system Peripheral nervous system
Aseptic meningitis 1 Autonomic disorder 1
Cerebrovascular disease 19 Cranial neuropathy 17
Demyelinating syndrome 2 Plexopathy 1
Headache 25 Polyneuropathy 5
Movement disorder 2 Psychosis 7
Myelopathy 1
Seizure disorder 11





fewer lesions, and smaller groups had 6–20 (24 patients)
or more 20 lesions (15 patients). Abnormal signal was
seen in the white matter with all types of clinical pre-
sentation and was frequently nonspecific, interpreted as
being consistent with focal ischemia, demyelination,
vasculitis, or other conditions. In 14 patients (16%), the
lesions had an extent or time-course which led the initial
readers to suggest the possibility of NP-SLE (Fig. 1).
Infarct-like lesions were seen in 21% of studies
(Fig. 2). Blood products, in the form of subarachnoid or
parenchymal hemorrhage, subdural hematoma, pete-
chial hemorrhage, or a hemorrhagic infarct, were de-
tected in six studies (5%). In some instances, gyriform
hemorrhage could not be reliably distinguished from
mineralizing laminar necrosis. Of the 93 examinations
with contrast-enhanced images, only 10 (11%) showed
abnormal intracranial enhancement, mainly focal and
heterogeneous. Other findings with a low frequency in-
cluded cystic encephalomalacia, meningeal contrast
enhancement, internal carotid artery occlusion, venous
angioma, iron deposition, vestibular schwannoma, and
deep venous sinus thrombosis. In three patients (4%),
MRI yielded alternative diagnoses not related to colla-
gen vascular disease, such as one vestibular schwannoma
and two cases of cervical spondylosis, accounting for the
symptoms.
Areas of restricted diffusion were seen in addition to
abnormalities on T2-weighted images in 12 of the
67 DWI studies (Fig. 3). Increased diffusion indicative
of vasogenic edema was observed in one study, the other
examinations demonstrating areas of restricted diffusion
indicative of ischemia or an infarct. MRA was positive
in five of 16 patients; in three it showed stenosis of the
left internal carotid artery, stenoses of the great vessels
and left internal carotid artery, and irregularity of the
carotid bulbs, but in the other two there were false-
positive findings: one equivocal aneurysm and one area
of diminished flow-related enhancement, not confirmed
on catheter angiography. One of the four patients who
underwent MRV had dural venous sinus thrombosis.
Catheter angiography, predictably, did not shown
changes of CNS vasculitis in any of the three patients.
All but two patients lost to clinical follow-up had at
least one follow-up rheumatology clinic note. Virtually
Table 3 Magnetic resonance imaging
Finding Number (%)
Normal 39 (34%)
White-matter lesions 70 (60%)






Contrast enhancement 10 (9%)
Diffusion abnormality 12/67 (18%)
Fig. 1 Typical white-matter lesions in neuropsychiatric systemic
lupus erythematosus (NP-SLE). Fluid-attenuated inversion-recov-
ery (FLAIR) image of a 48-year-old woman with an acute
confusional state. There are numerous foci of abnormal signal in
the white-matter of the frontal and parietal lobes. In the clinical
context, NP-SLE is the most likely diagnosis, although these lesions
could have many other causes
Fig. 2 Multiple infarcts. A 59-year-old man with SLE presenting
with dysphasia. T2-weighted image reveals an infarct in the left
frontal lobe involving gray and white matter. Other infarcts
involved different vascular territories. This patient also had
antiphospholipid syndrome
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all improved or remained stable on therapy; two patients
failed treatment. These were the only two to undergo
pathologic examination: one patient had a brain biopsy
revealing changes of CNS vasculitis and progressive
multifocal leukoencephalopathy, and in the other, the
only patient who died, post-mortem examination
showed no evidence of vasculitis.
The results of MRI by symptom category (Table 4a)
and by APL-Ab status (Table 4b) show a general trend
toward fewer normal studies and increasingly severe
imaging abnormalities as the severity and complexity of
symptoms and signs increase. A significantly higher
percentage of patients presenting with headaches had
normal or nearly normal MRI studies than patients with
complex symptoms (64 vs 19%) (P=0.04). White-matter
lesions were less frequent in patients with only head-
aches (34%) than in patients with focal or complex
presentations (64 and 71%, respectively), although these
differences did not reach statistical significance (P=0.14
and P=0.11). Infarcts were most frequent in patients
with severe symptoms (seizures, focal, or combined)
and were observed in significantly more patients with
focal or complex symptoms (26 and 35%, respectively)
than those without (P=0.05 andP=0.004). Infarcts were
found in a higher percentage of patients with APL-Ab
than without (27 vs 15%), but this also did not attain
statistical significance (P=0.20). Intracranial hemor-
rhage and diffusion abnormalities were not seen in
patients presenting with headaches only but were
observed in those with seizures, focal or global symptoms.
There were 14 patients with acute stroke-like deficits
(Table 5). These occurred in a higher percentage of pa-
tients with APL-Ab than in those without (23 vs 13%)
(P=0.22), although not a statistically significant differ-
ence. Abnormalities were seen on MRI in 11 (79%) of
the 14 patients, including eight with infarcts of varying
acuteness. DWI in three of these showed restricted dif-
fusion, consistent with acute infarcts. MRA showed
abnormalities in two of the patients, a left internal car-
otid artery occlusion and an atherosclerotic plaque at
the carotid bulb. All patients in this group received
treatment on presentation: 11 received had antithrom-
botic therapy, and 10 immunosuppression for suspected
lupus-related CNS vasculitis (Table 5).
We treated 36 patients medically for suspected NP-
SLE, of whom 20 had intravenous methylprednisolone
and/or cyclophosphamide. Only two patients had con-
comitant systemically active lupus, such as nephritis,
that also required intravenous therapy. Of the treated
patients 12 had MRI studies initially interpreted as
consistent with CNS lupus, based on the extent of white-
matter lesions and/or evidence of rapid progression on
short-term follow-up. The abnormalities were nonspe-
cific in 15, and in the other nine there was no active
lesion or no significant change from previous studies.
Treatment was discontinued in two patients after
their MRI was found to be normal, however three
received a full course of intravenous therapy despite
normal MRI.
Follow-up studies were available for 26 patients,
ranging from 4 days to 5 years. In eight of these patients
abnormalities progressed on follow-up MRI, three
showed regression, and 15 no change. All but one of the
patients eventually improved clinically, even in cases in
which the imaging abnormalities progressed.
Fig. 3a, b Abnormal diffusion. A 38-year-old woman with SLE
presenting with acute confusion and focal neurologic deficits. Axial
a FLAIR and b diffusion-weighted imaging demonstrate multiple
areas of restricted diffusion, consistent with ischemia. These are
nonspecific, and can be seen with embolic disease, microangiop-
athy, or inflammatory vasculitis
Table 4a, b MRI findings and
a by neurologic category,
b antiphospholipid antibody
status, per patient (%)
awithout focal symptoms








Headachea 11 (13) 7 (64) 4 (36) 1 (9) 2 (18) 0 (0) 0 (0)
Global 28 (33) 7 (25) 17 (61) 4 (14) 13 (46) 1 (4) 4 (14)
Focal 39 (46) 11 (28) 25 (64) 10 (26) 16 (41) 2 (5) 4 (10)
Seizurea 10 (12) 2 (20) 7 (70) 3 (30) 4 (40) 2 (20) 3 (30)
omplex 31 (36) 6 (19) 22 (71) 11 (35) 18 (58) 2 (6) 3 (10)
b. Antiphospholipid antibody status
Positive 30 (35) 6 (20) 24 (80) 8 (27) 6 (20) 2(7) 3(10)
Negative 55 (65) 23 (42) 31 (56) 8 (15) 19(35) 2(4) 7(13)
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Discussion
The underlying pathologic basis of NP-SLE has been the
subject of several investigations. Multiple microinfarcts,
noninflammatory thickening of small vessels with inti-
mal proliferation, small-vessel occlusion, and intracra-
nial embolism or hemorrhage have been observed in
pathologic specimens [16, 17, 18]. True vasculitis, with
inflammatory infiltrate and fibrinoid necrosis is rela-
tively rare, occurring in 6–9% of cases [17]. A bland
vasculopathy is most common, consisting of vascular
hyalinization, perivascular lymphocytosis, and endo-
thelial proliferation [3, 16, 17, 18]. Although the
underlying mechanisms are not understood and are
probably multifactorial, suggested mechanisms include
autoantibody-mediated activation of the thrombotic
system (as with APL-Ab); immune-complex mediated
vascular damage; and direct CNS attack by autoanti-
bodies, including antineuronal, antiribosomal P, and
antilymphocytotoxic antibodies [3, 4, 19].
Given that these mechanisms seem to have a final
common pathway involving the cerebral microvascula-
ture, it is not unexpected that MR has been shown to be
neither very sensitive nor specific in the diagnosis of NP-
SLE, estimates of sensitivity and specificity being in the
30 and 40%, respectively. Routine low-resolution (256
matrix) MRA, as used in our patients, is unlikely to be
sensitive enough to reveal caliber change in the small
and medium-sized vessels typically affected by SLE.
However, the clinical ramifications of this lack of spec-
ificity and sensitivity appear not to have been explored.
Previous studies have found MRI more likely to show
abnormalities in patients with focal rather than diffuse
deficits, showing a higher proportion of focal lesions and
infarcts [4, 9]. We also demonstrated increased fre-
quency of lesions in patients with focal and complex
rather than diffuse or global problems.
Perhaps the most important role of imaging in NP-
SLE is assessment of acute focal (stroke-like) neurologic
deficits. The differential diagnosis typically includes of
lupus-related CNS vasculitis, thromboembolic events
due to vasculopathy, APL-Ab- mediated thrombosis,
microangiopathy (including thrombotic thrombocyto-
penic purpura), Libman-Sacks endocarditis, and accel-
erated atherosclerosis; the pathogenesis in many patients
is probably multifactorial. Accurate assessment is cru-
cial, as treatment for these alternative diagnoses differs.
Immunosuppressive agents are typically used for sus-
pected vasculitis, while lifelong anticoagulation is the
mainstay of therapy for APL-Ab-mediated thrombo-
embolic events [20, 21]. Patients with APL-Ab have been
found to be at higher risk for unfavorable long-term
prognosis than other patients with SLE [22].
All 14 patients with acute focal neurologic deficits
were treated: 11 with antithrombotics (aspirin, couma-
din) and 10 with immunosuppression (steroids, cyclo-
phosphamide). Two patients with normal MRI and a
presumed transient ischemic attack and two with cere-
brovascular occlusion on MRA were appropriately tri-
aged to antithrombotic therapy. One patient with
increasing numbers of small lesions in gray and white
matter was treated for suspected CNS vasculitis with
steroids and cyclophosphamide. The seven patients who
were treatedwith both types of therapy tended to beAPL-
Table 5 Summary of 14 patients presenting with acute focal neu-
rological deficits. AC anticoagulants AM antimalarials APLS
antiphospholipid antibody syndrome AZA azathioprine CP
cyclophosphamide CS corticosteroids CVA cerebrovascular
accident DWI diffusion weighted imaging GM gray-matter
infarct(s) IV intravenous LICA left internal carotid artery NP-SLE
neuropsychiatric systemic lupus erythematosus TIA transient






39/F ) Subacute infarct,
MRA+ DWI+
Aspirin, AC Infarct, embolic
47/F + Multiple WM, MRA+ Aspirin, clopidogrel LICA occlusion,
APLS
47/F ) Old infarcts, no change IV-CS, CP TIA, NP-SLE
43/F ) Only mild volume loss IV-CS, CP NP-SLE
45/F + Recent infarct, DWI) CS, AC, CellCept APLS, NP-SLE
50/F ) Normal Aspirin TIA
47/F + GM, WM increasing Aspirin, clopidogrel TIA
48/F + Few WM, one new IV-CS, AC, aspirin Emboli/APLS
42/F ) Few WM AC, aspirin, IV-CS
initially
TIA
59/M + GM, WM, one new CS, AZA, AC TIA, APLS,
?NP-SLE
31/F + GM, WM, stable Aspirin, IV-CS, AC, AM CVA, ?NP-SLE
21/F ) GM, WM, DWI+ CS, aspirin NP-SLE, conversion
32/F ) GM, WM, DWI+ IV-CS, CP, aspirin CVA, ?vasculitis
28/F + Few WM Aspirin, CS TIA
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Ab positive (five) and to have multiple gray and white
matter abnormalities (Fig. 2). DWI in two such patients
showed restricted diffusion suggestive of ischemic foci,
but DWI did not seem to further differentiate inflam-
matory vasculitis, thromboembolic disease, or bland
vasculopathy. These patients notes reflected clinical
uncertainty as to the underlying pathophysiology, espe-
cially the presence of vasculitis. The fact that they were
treated with both anti-SLE and antithrombotic agents
(typically prednisone and aspirin) suggests that it is not
necessarily possible to distinguish thrombotic or inflam-
matory events, or both, using clinical and MRI data.
Most of our patients with normal or nearly normal
MRI imaging did not undergo specific therapy for SLE.
They tended to have minor deficits or symptoms or
signs not necessarily expected to improve with therapy
(hearing loss, cognitive decline). However, three received
a full course of high-dose intravenous steroids or pulsed
cyclophosphamide based on clinical and laboratory
findings alone, without imaging evidence of active disease,
suggesting that in the clinicians view, MRI lacked sensi-
tivity in this subgroup. One such patient presented with
fever, headaches, and myalgia with increased cerebrospi-
nal fluid protein, elevated sedimentation rate and
C-reactive protein. Another presented with severe head-
aches, serositis, and normal laboratory tests, and the third
with refractory hallucinations and normal laboratory
values. Although the possibility of spontaneous remission
cannot be excluded, the fact that these patients improved
clinically having received anti-SLE therapy suggests that
a small number of patients with normal MRI may
nevertheless have treatable NP-SLE.
Recent investigations have shown a correlation be-
tween antineuronal autoantibodies and diffuse CNS
disease in SLE [1, 4, 19]. The imaging features of such
autoantibody-mediated disease are not known, but it is
plausible that diffuse CNS attack at a molecular level
may escape detection on conventional MRI. While
serologic tests and clinical judgment remain the main-
stay of diagnosis and management of these cases, more
sensitive imaging techniques such as MR spectroscopy
hold promise in detection of subclinical metabolic brain
abnormalities in SLE [23, 24, 25, 26, 27, 28]. Perfusion
MRI shown promise for detecting ischemic areas in
CNS vasculitis that had escaped detection by conven-
tional MRI [29].
DWI and diffusion tensor imaging also may be use-
ful. A recent investigation of DWI in SLE [30] suggests
two major patterns of abnormality: restricted diffusion,
suggestive of cytotoxic edema seen with vascular occlu-
sion; and increased diffusion suggestive of vasogenic
edema, seen with vasculopathy. We had ten patients
with areas of abnormal diffusion; one patient had small
areas of restricted diffusion on a background of increased
diffusion (vasogenic edema), while the others had re-
stricted diffusion, indicative of an infarct. Notably, six
patients whose serial MRI showed improvement or
worsening, but none of thosewith stable appearances, had
positiveDWI. This suggests thatDWImay be amarker of
‘‘active’’ disease, and diffusion abnormalities should at
least be taken as an indication for follow-up MRI.
Potential pitfalls in these patients include, for example,
an SLE/multiple sclerosis overlap syndrome, described
previously [31, 32]. In such patients it can be difficult or
impossible to ascribe inflammatory-type signal abnor-
malities to NP-SLE or demyelinating disease with
certainty. Opportunistic infection related to immuno-
suppression is another potential pitfall, as in one of our
patients (Fig. 4) who failed to respond to therapy andwas
found to have progressive multifocal leukoencephalopa-
thy on brain biopsy [33]. This underscores the lack of
specificity of conventionalMRI in the face of concomitant
infection, an important consideration given that infection
may be exacerbated by immunosuppressive anti-SLE
therapy.
We have attempted to examine the current role of
MRI in the management of neuropsychiatric SLE. Al-
though it is useful in the majority of patients with sus-
pected NP-SLE, we had several in whom the
abnormalities did not serve to triage patients appropri-
ately to antithrombotic or immunosuppressive therapy.
On the other hand, patients with normal MRI may have
deficits which warrant treatment on clinical grounds
alone, suggesting a lack of sensitivity of our imaging
strategy. The general reluctance to proceed to biopsy,
and reliance on empiric therapy underscores the need for
more sensitive noninvasive imaging. Our findings make
the case for the investigation of newer techniques in the
investigation of suspected NP-SLE.
Fig. 4 SLE and progressive multifocal leukoencephalopathy. A 57-
year-old man with SLE, on chronic immunosuppression, present-
ing with visual disturbance. After he failed to improve with
treatment for vasculitis, brain biopsy showed evidence of vasculitis
with concomitant JC virus inclusion bodies
20
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